Development of synthetic biotics as treatment for human diseases | Zendy

Aoife M. Brennan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of synthetic biotics as treatment for human diseases

Author(s) -

Aoife M. Brennan

Publication year - 2022

Publication title -

synthetic biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.769

H-Index - 8

ISSN - 2397-7000

DOI - 10.1093/synbio/ysac001

Subject(s) - synthetic biology , microbiology and biotechnology , computational biology , medicine , biology

Advances in synthetic biology have allowed the generation of strains of bacteria that are genetically altered to have specific therapeutic benefits. These synthetic biotics, also widely referred to as engineered living therapeutics, have tremendous potential as a new therapeutic modality, and several have advanced into the clinic and human testing. This review outlines some of the unique attributes of synthetic biotics as well as some of the challenges in their development as prescription products. Regulatory considerations are discussed, and a case study of a program that has advanced into Phase 2 testing is provided: SYNB1618 for the treatment of PKU.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research